1. Home
  2. GDHG vs BTAI Comparison

GDHG vs BTAI Comparison

Compare GDHG & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Golden Heaven Group Holdings Ltd.

GDHG

Golden Heaven Group Holdings Ltd.

HOLD

Current Price

$1.85

Market Cap

38.1M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDHG
BTAI
Founded
2008
2017
Country
China
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.1M
35.6M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
GDHG
BTAI
Price
$1.85
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.33
AVG Volume (30 Days)
5.5K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$261.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$1.17
52 Week High
$8.69
$8.08

Technical Indicators

Market Signals
Indicator
GDHG
BTAI
Relative Strength Index (RSI) 45.39 42.83
Support Level $1.83 $1.33
Resistance Level $2.30 $2.20
Average True Range (ATR) 0.15 0.15
MACD 0.02 -0.01
Stochastic Oscillator 61.66 11.84

Price Performance

Historical Comparison
GDHG
BTAI

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: